Here’s what leading experts in Alzheimer’s are saying about research and innovation.

Test Name
Test Title, Test Company

Read biography×

Here’s what leading experts in Alzheimer’s are saying about research and innovation.

Dr. Bill Chin
Chief Medical Officer and EVP, PhRMA

Read biography×

Dr. Bill Chin
Chief Medical Officer and EVP, PhRMA

Follow Bill on:

Dr. Bill Chin leads PhRMA’s Scientific & Regulatory Affairs department. A physican, an endocrinologist and an academic at heart, Dr. Chin envisions establishing PhRMA as the premiere convener in advancing drug discovery and development, regulatory sciences and collaborative partnerships.

×

Here’s what leading experts in Alzheimer’s are saying about research and innovation.

George Scangos
CEO, Biogen

Read biography×

George Scangos
CEO, Biogen

George A. Scangos, Ph.D., is our Chief Executive Officer and has served in this position and as a member of our Board of Directors since July 2010. From 1996 to July 2010, Dr. Scangos served as the President and Chief Executive Officer of Exelixis, Inc., a drug discovery and development company, where he continues to serve on the board. From 1993 to 1996, Dr. Scangos served as President of Bayer Biotechnology, where he was responsible for research, business development, process development, manufacturing, engineering and quality assurance of Bayer’s biological products. Before joining Bayer in 1987, Dr. Scangos was a professor of biology at Johns Hopkins University for six years, where he is still an adjunct professor. Dr. Scangos served as non-executive Chairman of Anadys Pharmaceuticals, Inc., a biopharmaceutical company, from 2005 to July 2010 and was a director of the company from 2003 to July 2010. He also served as the Chair of the California Healthcare Institute in 2010 and was a member of the board of the Global Alliance for TB Drug Development until 2010.

Dr. Scangos is Chairman-Elect of the Board of Directors of Pharmaceutical Research and Manufacturers of America (PhRMA), a member of the Boards of Trustees of the Boston Museum of Science and the Biomedical Science Careers Program, and a member of the National Board of Visitors of the University of California, Davis School of Medicine. Dr. Scangos is also on the Board of Directors of Agilent Technologies, Inc., a provider of bioanalytical and electronic measurement solutions.

 

×

Here’s what leading experts in Alzheimer’s are saying about research and innovation.

Sue Peschin
President and CEO, Alliance for Aging Research

Read biography×

Sue Peschin
President and CEO, Alliance for Aging Research

Sue Peschin, MHS, is president and CEO at the Alliance for Aging Research. As the leader of the Executive Team, she is responsible for successful execution of the current strategic plan, and for assuring the operational excellence, fiscal health and growth of the organization.

Sue has more than 20 years of experience in health policy, government relations and non-profit leadership.  Prior to her current role, she was vice president of Public Policy for the Alzheimer’s Foundation of America (AFA), where she successfully advocated for passage of health reform provisions for individuals with dementia and family caregivers, including the “detection of any cognitive impairment” provision in the new annual Medicare wellness visit, nursing home transparency and the Independence at Home Act demonstration program.

While at AFA, Sue also achieved a doubling of appropriations for the Missing Alzheimer’s Disease Patient Alert Program, co-facilitated the Leaders Engaged in Alzheimer’s Disease coalition, and served as an advisor on the “Caregiver Initiative” included in the 2010 annual report for the Middle Class Task Force, chaired by Vice President Joe Biden.  She has published studies on cognitive screening, federal funding at the National Institute on Aging and policy recommendations for implementation of the National Alzheimer’s Project Act.

Previous to her work at AFA, Sue ran her own consulting business, offering lobby day training and strategic planning services. She also worked for more than 10 years in firearms violence prevention at the Violence Policy Center and Consumer Federation of America, and she continues as a Board member of CeaseFire Maryland. She also currently serves as a Board member for the American Aging Association, as a Steering Committee member for the Coalition for Imaging & Bioengineering Research, and as a member of the Expert Panel on Respite Research convened by the Lifespan Respite TA Center at the ARCH National Respite Network and Resource Center in collaboration with the Administration for Community Living/Administration on Aging.

Sue earned an B.A. in Sociology from Brandeis University and an M.H.S. degree in Health Policy from the Johns Hopkins University Bloomberg School of Public Health.

×

Here’s what leading experts in Alzheimer’s are saying about research and innovation.

Robert Egge
VP, Public Policy, Alzheimerʼs Association

Read biography×

Robert Egge
VP, Public Policy, Alzheimerʼs Association

Follow Robert on:

Robert Egge is the Alzheimer’s Association’s Vice President of Public Policy. With policy experience in Alzheimer’s and related health care issues, Mr. Egge leads the Association’s Public Policy division based in Washington, DC. The division includes federal affairs, state affairs, public health and grassroots advocacy teams working in pursuit of policies to better serve those affected by Alzheimer’s disease and related disorders. Chief among these priorities are increasing federal support for Alzheimer’s research and treatment development, enhancing Alzheimer’s care and support, and improving Alzheimer’s planning, coordination and execution by federal and state agencies. 

In his previous position as Executive Director of the Alzheimer’s Study Group, Mr. Egge led a review of the broad range of challenges posed to the nation by the mounting Alzheimer crisis, and opportunities to address them. The Alzheimer’s Study Group, a blue ribbon task force of national leaders co-chaired by former House Speaker Newt Gingrich and former Nebraska Senator Bob Kerrey, was created to develop a national strategic plan to address Alzheimer’s disease. Mr. Egge worked closely with Gingrich, Kerrey and other Alzheimer’s Study Group members including Justice Sandra Day O’Connor, Dr. Mark McClellan, Dr. Harold Varmus and Dr. David Satcher to shape and develop the group’s national assessment, strategy and specific policy proposals. 

Mr. Egge’s editorials have appeared in a variety of newspapers including the New York Times, the Financial Times, and Business Week. He has also testified before various committees in the U.S. House and Senate on Alzheimer’s policy, and has given frequent television, radio and print interviews on Alzheimer’s and other aspects of health care policy. 

×

07/30/14: We’ve seen great strides to treat arthritis and related diseases. How do we continue to make headway to improve the lives of patients?

Back to Top

Contributors:

            
James P. Sullivan, Ph.D., VP, Pharmaceuticals Discovery, AbbVie
Stephen I. Katz, Director, NIAMS
Amanda Niskar, National Scientific Director, Arthritis Foundation
Christopher F. Smith, CEO, Arthritis Foundation, GLR
Gabriela Lavezzari, AVP, Scientific Affairs , PhRMA
NPF, Partner, Arthritis Contributor

Join The Conversation

07/24/14: What key benefits of personalized medicine do you think the public needs to know about in order to embrace this approach to health care?

Back to Top

Contributors:

          
Amy Miller, Executive Vice President, PMC
Raju Kucherlapati, Professor, Department of Genetics, Harvard Medical School
Donna R. Cryer, JD, President & CEO, Global Liver Institute
Randy Burkholder, VP, Policy, PhRMA
Mark Richards, Senior Vice President, Management Supervisor, KRC Research

Join The Conversation

06/17/14: As Americans live longer, how can we tackle aging as a major risk factor for chronic disease?

Back to Top

Contributors:

                
Bob Blancato , Executive Director, NANASP
Cynthia A. Bens, Vice President, Public Policy, Alliance for Aging Research
Dorothy Leone-Glasser, President and CEO, ARxC
Jamesetta Smith, President, Lupus Foundation AR
Paul Downey, President and Chief Executive Officer, Serving Seniors
Thair Phillips, President, RetireSafe
Rob Gundermann, Public Policy Director, ADAW
James Adams, Chairman, Granite State Taxpayers

Join The Conversation

Pages